Full-Time

Country Study Operations Manager

Icon

Icon

10,001+ employees

Global drug and device development services

No salary listed

Company Does Not Provide H1B Sponsorship

Ambler, PA, USA

Remote

Remote in the United States; US work eligibility required.

Bachelor's, Master's, MBA

Category
Biology & Biotech (1)
Required Skills
Risk Management

Get referred to Icon

See people who can refer or advise you

Requirements
  • BS/BSc/MS/MSc degree required
  • A scientific or technical degree is preferred along with knowledge of clinical trial methodology
  • BA/BS 5+ years of relevant experience operational clinical trial experience
  • MBA/MS/ 3+ years of relevant experience operational clinical trial experience
  • Working knowledge of Good Clinical Practice, clinical and regulatory operations and environment in countries under responsibility
  • Demonstrated clinical research experience and/or study management/startup project manager experience
  • Demonstrated experience in managing country level operational activities and/or vendors
  • Experience in Study and Quality management and working in a matrix management environment
  • Expertise in the use of study/site dashboard and reporting tools
  • Detail oriented & possesses technical expertise
  • Ability to manage moderately complex processes
  • Ability to operate in a matrix environment
  • Risk Identification & Mitigation
  • Strategic Planning, Analytical and Problem-Solving Skills
  • Critical Path Analysis
  • Excellent communication skills, both written and verbal
  • Ability to adapt to changing technologies and processes
  • Effective verbal and written communication skills in relating to colleagues and associates both
Responsibilities
  • Responsible for management/oversight of study and regional/country level activities from study startup through conduct and study close
  • May manage the study start up process in countries assigned (where SUPM not assigned) and/or oversee pCRO responsible for these activities as applicable
  • Through the Site Care Partner/Country Trial Manager or pCRO supports the Country/investigator outreach process, site identification and feasibility ensuring countries/sites can meet all study protocol requirements
  • Provides country level input on Startup and Recruitment milestones as provided by pCRO and/or Country Trial Manager/Site Care Partner to Global Study Manager during planning
  • Is accountable for overseeing pCRO and/or Country Trial Manager/Site Care Partner for assigned studies at country level in accordance with the overall project plan, manages and maintains accurate country level plans (e.g. timelines, budget, risk and quality plans)
  • Collaborates with accountable roles to identify and manage deviations and risks in study startup and execution and implements mitigation strategies as required. Is also accountable for resolution of Site Activation escalations to Study Teams including offering options for mitigation
  • Leader of the Local Study Team (core members: (Lead) Site Care Partners Clinical Trial Assistant, ad hoc members: ICL, Site Activation Partner, CTRO and Local Regulatory, Medical Affairs colleagues and other key stakeholders as required)
  • Ensures compliance to relevant Global and Local, internal and external requirements and regulations
  • Ensures timely communication bidirectionally between the global and local study team.
  • Provides protocol level guidance and support to responsible Local Study Team members as applicable.
  • Liaise with Site Care Partner, Lead Site Care Partner, Site Activation Partners and Regulatory colleagues in country to agree on submission strategy to Health Authorities and Ethic Committees
  • Utilize roles in countries such as Lead Site Care Partner, and expert roles such as Contracts Leads, Site Activation Partners to provide the Global Teams with local intelligence and operational nuances to be considered
  • Acts as the study level point of contact for all study-level questions for the Local Study Team, ensuring resolution at lowest possible level, and when needed liaising with and escalating to appropriate global roles/teams
  • Follows up on region/country level issue status to ensure resolution.
  • Identifies country level trends to improve deliverables processes as needed
  • Utilizes country intelligence to provide input on country specific risks into preparation of Investigational Quality Management Plan, Study Monitoring Plans, ensures PTMF completeness and oversight of all relevant compliance activities for allocated studies
  • Ensures audit/Inspection readiness during start-up and conduct
  • Manages applicable Quality Events with pCRO and local team as applicable and required
  • Coordinates effective site recruitment planning to allow for implementation of plans at the country and site level, consistent with global plan and local targets
  • Responsible to drive and ensure delivery of data cleaning deliverables for pCRO and sites as applicable
  • Provides input on Country level Per Subject Costs, local vendor costs and other fees where applicable
  • May act as a Subject Matter Expert
  • May lead operational effectiveness initiatives at country or regional level
  • Responsible for PTA and SIV report review for reports completed by the Site Care Partner
  • Supports implementation of client’s Site Technology Experience systems (e.g. Shared Investigator Platform SIP, Centralized Account Management CAM)
  • Support to EC/RA and other relevant submissions and deficiency/query responses for initial and subsequent CTA submissions within required timelines
  • Drives pCRO and/or applicable internal study team members to ensure PTMF set up meets study requirements, and maintains oversight of PTMF completeness
  • Provides country level documents to PTMF and maintains oversight of Investigator Site File (ISF) reconciliation and completeness actions
  • Ensure pCRO and/or applicable internal study team members maintain appropriate level IP/equipment/ancillary supplies management including Import/Export License management with the support of Clinical Trial Assistants and other roles as required
  • Supports implementation of new tools and technologies (e.g. eConsent, eISF, Remote Source Access, remote SDV/SDR, iConnect, implementation of protocol required decentralized trial options etc.)
  • Support Identification, contract development and management of local vendors or facilities as per protocol
  • Investigator Meeting support and management including doing presentations as appropriate
  • Management of local Investigator Meetings including doing presentations as appropriate

Provides consulting, development, and commercialization services for drugs and medical devices through a global network to help clients accelerate development and bring products to market. A global team of experts in 53 countries offers end-to-end support across strategy, development, regulatory, manufacturing, and market access to reduce time to market, lower costs, and improve quality. The company differentiates itself with its large global presence, clear focus on speed and cost, and extensive experience across therapeutic areas. Its goal is to help clients accelerate the development of life-saving drugs and devices by delivering high-quality information, solutions, and performance.

Company Size

10,001+

Company Stage

IPO

Headquarters

Ireland

Founded

1990

Get referred to Icon

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue rose 1.2% year over year to $2.06 billion.
  • Gross bookings climbed 24.1% year over year, signaling stronger biotech demand.
  • Closing Symphony Health on May 8, 2026 sharpened focus on core clinical research.

What critics are saying

  • Audit Committee restatements cut 2024 revenue $92.7 million and exposed material weaknesses.
  • 2026 revenue guidance of $7.85 billion to $8.15 billion trails 2025's $8.25 billion.
  • Debt refinancing through April 2027 bridge financing leaves maturity pressure unresolved.

What makes Icon unique

  • ICON’s 23.4 billion backlog and 1.51x Q2 2026 book-to-bill beat peers.
  • Anthropic and Microsoft partnerships embed Orbis AI across trial planning and execution.
  • Global scale still matters: 40,200 employees across 99 locations in 55 countries.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Paid Vacation

401(k) Retirement Plan

Mental Health Support

Life Insurance

Flexible Work Hours

Growth & Insights and Company News

Headcount

6 month growth

29%

1 year growth

31%

2 year growth

31%
MarketBeat
Aug 11th, 2026
Insider selling: Icon (NASDAQ:ICLR) CEO sells $62,674.74 in stock.

Insider selling: Icon (NASDAQ:ICLR) CEO sells $62,674.74 in stock. August 11, 2026 Key points. * Icon CEO Barry Edward Balfe sold 382 shares for approximately $62,675, reducing his direct holdings by 7.37%. The sale was made to cover tax withholding obligations tied to vested equity awards. * Icon reported quarterly EPS of $2.56, narrowly exceeding estimates, while revenue reached $2.06 billion and increased 2.3% year over year. * Analyst sentiment is mixed, with a consensus rating of "Hold" and an average price target of $170.40; institutional investors own 95.61% of the company. * MarketBeat previews the top five stocks to own by September 1st. Icon Plc (NASDAQ:ICLR - Get Free Report) CEO Barry Edward Balfe sold 382 shares of the stock in a transaction on Monday, August 10th. The shares were sold at an average price of $164.07, for a total value of $62,674.74. Following the sale, the chief executive officer directly owned 4,804 shares in the company, valued at approximately $788,192.28. The trade was a 7.37% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Icon price performance. Icon stock traded down $0.47 during midday trading on Tuesday, reaching $165.58. 656,816 shares of the company were exchanged, compared to its average volume of 1,388,886. The firm's 50-day simple moving average is $160.91 and its 200-day simple moving average is $134.45. Icon Plc has a 1 year low of $66.57 and a 1 year high of $203.91. The company has a market capitalization of $12.68 billion, a price-to-earnings ratio of 38.87, a P/E/G ratio of 6.82 and a beta of 1.21. The company has a debt-to-equity ratio of 0.23, a quick ratio of 0.95 and a current ratio of 0.95. Icon (NASDAQ:ICLR - Get Free Report) last released its earnings results on Thursday, July 30th. The medical research company reported $2.56 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.55 by $0.01. The company had revenue of $2.06 billion for the quarter, compared to analyst estimates of $2 billion. Icon had a net margin of 3.99% and a return on equity of 8.02%. The firm's quarterly revenue was up 2.3% on a year-over-year basis. During the same period in the prior year, the firm earned $3.26 EPS. On average, analysts anticipate that Icon Plc will post 9.57 EPS for the current year. Analyst ratings changes. ICLR has been the subject of several recent analyst reports. Leerink Partners set a $145.00 target price on shares of Icon in a research note on Thursday, May 28th. Truist Financial reissued a "buy" rating and set a $209.00 price target (up from $207.00) on shares of Icon in a research note on Friday, July 31st. UBS Group set a $160.00 price objective on Icon in a report on Wednesday, June 24th. JPMorgan Chase & Co. lifted their price objective on Icon from $130.00 to $155.00 and gave the company a "neutral" rating in a research report on Thursday, June 25th. Finally, William Blair upgraded Icon to a "strong-buy" rating in a research note on Thursday, July 30th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, seven have assigned a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Hold" and an average price target of $170.40. Discover more Market cap calculator AI infrastructure stocks Mathematics Institutional investors weigh in on Icon. A number of institutional investors have recently bought and sold shares of ICLR. WINTON GROUP Ltd purchased a new position in Icon during the second quarter worth approximately $254,000. Daiwa Securities Group Inc. grew its stake in shares of Icon by 19.3% during the 2nd quarter. Daiwa Securities Group Inc. now owns 28,145 shares of the medical research company's stock valued at $4,094,000 after buying an additional 4,546 shares during the period. Frontier Capital Management Co. LLC grew its stake in shares of Icon by 97.6% during the 2nd quarter. Frontier Capital Management Co. LLC now owns 71,360 shares of the medical research company's stock valued at $10,379,000 after buying an additional 35,253 shares during the period. Peapack Gladstone Financial Corp acquired a new stake in shares of Icon during the 2nd quarter worth $212,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Icon by 58.7% in the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 781 shares of the medical research company's stock worth $113,000 after buying an additional 289 shares during the period. 95.61% of the stock is currently owned by hedge funds and other institutional investors. About Icon. Icon plc NASDAQ: ICLR is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas. Icon's service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Continue following MarketBeat Before you consider Icon, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Icon wasn't on the list. While Icon currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys. The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you'll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

StreetInsider
Aug 6th, 2026
ICON prices $2.15B in senior unsecured notes to refinance debt

ICON plc has priced $2.15 billion in senior unsecured notes through its subsidiary, ICON Investments Six Designated Activity Company. The offering comprises three tranches: $500 million of 5.064% notes due 2029, $1.0 billion of 5.421% notes due 2031, and $650 million of 5.995% notes due 2036. The notes will be guaranteed by ICON on a senior unsecured basis. The offering is expected to close on 13 August 2026, subject to customary closing conditions. ICON intends to use proceeds to repay all outstanding borrowings under its bridge facility credit agreement, repay all outstanding senior secured term loans, and redeem its 5.809% Senior Secured Notes due 2027. Upon repayment, collateral securing ICON's revolving credit facility will be automatically released.

Yahoo Finance
Aug 5th, 2026
ICON shares jump 33% in three months on $29.7B backlog and improving biotech demand

ICON Public Limited Company shares rose 33.2% over three months amid strengthening recovery signs in clinical research demand. Request-for-proposal flow increased 22% sequentially in Q2 2026, with Phase III programmes representing about 50% of opportunity volume. Gross bookings reached $3.68 billion, up 24.1% year-over-year, whilst net business wins totalled $3.12 billion. The book-to-bill ratio stood at 1.51X. Backlog grew 3% sequentially to $23.4 billion, improving revenue visibility. However, second-quarter adjusted EBITDA declined 21.7% year-over-year to $327.2 million, whilst adjusted earnings fell to $2.56 per share from $3.52. Higher pass-through revenues supported sales but pressured margins. Analysts expect 2026 revenues to decline 1% and earnings to fall 15.3% year-over-year.

Business Wire
Jul 31st, 2026
ICON shareholders approve all resolutions at annual general meeting

ICON plc, a clinical research organisation, announced that shareholders approved all resolutions at its Annual General Meeting held on 31 July 2026. The resolutions, which were sent to shareholders on 26 June 2026, included the re-election of several board members and the election of new directors. The approved resolutions covered various corporate governance matters, including authorising the company to allot shares, disapply statutory pre-emption rights, and make overseas market purchases of shares. Shareholders also authorised the price range for reissuing treasury shares. Headquartered in Dublin, ICON employed approximately 40,200 people across 99 locations in 55 countries as of 30 June 2026. The company provides clinical development and commercialisation solutions to pharmaceutical, biotechnology, medical device, and public health organisations worldwide.

Yahoo Finance
Jul 28th, 2026
ICON partners with Anthropic to deploy Claude AI across clinical trial lifecycle

ICON plc has announced a multi-year collaboration with Anthropic to integrate Claude's AI capabilities throughout the clinical trial lifecycle. The partnership will advance ICON's Orbis platform, developing four production capabilities: site intelligence and study planning, predictive intelligence for enrolment risks, protocol optimisation, and ecosystem integration. ICON will deploy Claude across its organisation through role-based implementations, including Claude Code for developers and Claude Science for scientific teams. The collaboration will strengthen Orbis's intelligence layer, connecting ICON's expertise and data across trials. Chief Executive Officer Barry Balfe stated the partnership aims to accelerate clinical trials by combining ICON's clinical development expertise with Anthropic's frontier AI capabilities, helping sponsors make better decisions and execute studies with greater precision.